---
schema_version: "secwatch.filing_event.v1"
accession: "0001193805-25-000212"
form_type: "8-K"
ticker: "IMUX"
cik: "0001280776"
company_name: "IMMUNIC, INC."
filed_at: "2025-02-20T23:59:59+00:00"
generated_at: "2026-05-26T08:06:21.121335+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Immunic's IMU-856 shows dose-dependent GLP-1 increase in celiac trial; preclinical weight loss

## Summary
- Post-hoc phase 1b analysis: dose-dependent GLP-1 increase up to 250% vs placebo; p=0.014 (80mg) and p=0.003 (160mg).
- Preclinical 6-month study: IMU-856 reduced body weight gain and food consumption up to -40% vs control in a dose-dependent manner.
- Program is Phase 2 ready; company plans to explore IMU-856 as oral treatment for obesity (market >$170B by 2031).
- Data also presented at ECCO 2025 digital oral presentation; webcast held Feb 20, 2025.

## SEC filing metadata
- accession: 0001193805-25-000212
- form_type: 8-K
- ticker: IMUX
- cik: 0001280776
- company_name: IMMUNIC, INC.
- filed_at: 2025-02-20T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1280776/000119380525000212/0001193805-25-000212-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1280776/000119380525000212/e664213_8k-immunic.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193805-25-000212
- JSON: https://secwatch.observer/filing/0001193805-25-000212.json
- Plain text: https://secwatch.observer/filing/0001193805-25-000212.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.